Residual tricuspid regurgitation after tricuspid transcatheter edge-to-edge repair: Insights into the EuroTR registry.
Procedural success
Residual tricuspid regurgitation
Tricuspid regurgitation
Tricuspid regurgitation reduction
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
29 May 2024
29 May 2024
Historique:
revised:
05
04
2024
received:
27
02
2024
accepted:
23
04
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
Data on the prognostic impact of residual tricuspid regurgitation (TR) after tricuspid transcatheter edge-to-edge repair (T-TEER) are scarce. The aim of this analysis was to evaluate 2-year survival and symptomatic outcomes of patients in relation to residual TR after T-TEER. Using the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) we investigated the impact of residual TR on 2-year all-cause mortality and New York Heart Association (NYHA) functional class at follow-up. The study further identified predictors for residual TR ≥3+ using a logistic regression model. The study included a total of 1286 T-TEER patients (mean age 78.0 ± 8.9 years, 53.6% female). TR was successfully reduced to ≤1+ in 42.4%, 2+ in 40.0% and 3+ in 14.9% of patients at discharge, while 2.8% remained with TR ≥4+ after the procedure. Residual TR ≥3+ was an independent multivariable predictor of 2-year all-cause mortality (hazard ratio 2.06, 95% confidence interval 1.30-3.26, p = 0.002). The prevalence of residual TR ≥3+ was four times higher in patients with higher baseline TR (vena contracta >11.1 mm) and more severe tricuspid valve tenting (tenting area >1.92 cm T-TEER effectively reduced TR severity in the majority of patients. While residual TR ≥3+ was associated with worse outcomes, no differences were observed for residual TR 1+ versus 2+. Symptomatic improvement correlated with the degree of TR reduction.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Roman Pfister
(R)
Stephan Baldus
(S)
Muhammed Gerçek
(M)
Felix Rudolph
(F)
Sebastian Ludwig
(S)
Christoph Pauschinger
(C)
Leonhard-Moritz Schneider
(LM)
Dominik Felbel
(D)
Carsten Salomon
(C)
Harald Lapp
(H)
Tania Puscas
(T)
Alain Berrebi
(A)
Amir Abbas Mahabadi
(AA)
Florian Schindhelm
(F)
Berenice Caneiro-Queija
(B)
Julio C Echarte
(JC)
Jürgen Schreieck
(J)
Andreas Goldschmied
(A)
Edoardo Pancaldi
(E)
Daniela Tomasoni
(D)
Natacha Rousse
(N)
Samy Aghezzaf
(S)
Norbert Frey
(N)
Martin Kraus
(M)
Sebastian Rosch
(S)
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, et al. Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 2014;7:1185–1194. https://doi.org/10.1016/j.jcmg.2014.07.018
Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433–442. https://doi.org/10.1016/j.jcmg.2018.06.014
Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long‐term survival. J Am Coll Cardiol 2004;43:405–409. https://doi.org/10.1016/j.jacc.2003.09.036
Stolz L, Doldi PM, Weckbach LT, Stocker TJ, Braun D, Orban M, et al. Right ventricular function in transcatheter mitral and tricuspid valve edge‐to‐edge repair. Front Cardiovasc Med 2022;9:993618. https://doi.org/10.3389/fcvm.2022.993618
Orban M, Rommel KP, Ho EC, Unterhuber M, Pozzoli A, Connelly KA, et al. Transcatheter edge‐to‐edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail 2020;8:265–276. https://doi.org/10.1016/j.jchf.2019.12.006
Mehr M, Taramasso M, Besler C, Ruf T, Connelly KA, Weber M, et al. 1‐year outcomes after edge‐to‐edge valve repair for symptomatic tricuspid regurgitation: Results from the TriValve registry. JACC Cardiovasc Interv 2019;12:1451–1461. https://doi.org/10.1016/j.jcin.2019.04.019
Stolz L, Doldi PM, Kresoja KP, Bombace S, Koell B, Kassar M, et al. Applying the TRILUMINATE eligibility criteria to real‐world patients receiving tricuspid valve transcatheter edge‐to‐edge repair. JACC Cardiovasc Interv 2024;17:535–548. https://doi.org/10.1016/j.jcin.2023.11.014
Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al.; TRILUMINATE Pivotal Investigators. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–1842. https://doi.org/10.1056/NEJMoa2300525
Higuchi S, Orban M, Stolz L, Karam N, Praz F, Kalbacher D, et al. Impact of residual mitral regurgitation on survival after transcatheter edge‐to‐edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv 2021;14:1243–1253. https://doi.org/10.1016/j.jcin.2021.03.050
Sugiura A, Tanaka T, Kavsur R, Öztürk C, Vogelhuber J, Wilde N, et al. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge‐to‐edge tricuspid repair. JACC Cardiovasc Interv 2021;14:2260–2270. https://doi.org/10.1016/j.jcin.2021.07.048
Stolz L, Orban M, Besler C, Kresoja KP, Braun D, Doldi P, et al. Cardiohepatic syndrome is associated with poor prognosis in patients undergoing tricuspid transcatheter edge‐to‐edge valve repair. JACC Cardiovasc Interv 2022;15:179–189. https://doi.org/10.1016/j.jcin.2021.10.033
Hausleiter J, Braun D, Orban M, Latib A, Lurz P, Boekstegers P, et al. Patient selection, echocardiographic screening and treatment strategies for interventional tricuspid repair using the edge‐to‐edge repair technique. EuroIntervention 2018;14:645–653. https://doi.org/10.4244/EIJ‐D‐17‐01136
Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270. https://doi.org/10.1093/ehjci/jev014
Hahn RT, Thomas JD, Khalique OK, Cavalcante JL, Praz F, Zoghbi WA. Imaging assessment of tricuspid regurgitation severity. JACC Cardiovasc Imaging 2019;12:469–490. https://doi.org/10.1016/j.jcmg.2018.07.033
Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge‐to‐edge repair. JACC Cardiovasc Interv 2018;11:1119–1128. https://doi.org/10.1016/j.jcin.2018.05.002
Webb JG, Chuang AM, Meier D, von Bardeleben RS, Kodali SK, Smith RL, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1‐year outcomes of a multicenter, first‐in‐human experience. JACC Cardiovasc Interv 2022;15:481–491. https://doi.org/10.1016/j.jcin.2022.01.280
Kodali S, Hahn RT, George I, Davidson CJ, Narang A, Zahr F, et al.; TRISCEND Investigators. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30‐day results. JACC Cardiovasc Interv 2022;15:471–480. https://doi.org/10.1016/j.jcin.2022.01.016
Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: A multicenter, observational, first‐in‐human experience. JACC Cardiovasc Interv 2021;14:501–511. https://doi.org/10.1016/j.jcin.2020.11.045
Weckbach LT, Stolz L, Chatfield AG, Fam NP, von Bardeleben RS, Davidson CJ, et al. Right ventricular reverse remodeling after transcatheter tricuspid valve replacement in patients with heart failure. J Am Coll Cardiol 2023;81:708–710. https://doi.org/10.1016/j.jacc.2022.12.005
Orban M, Braun D, Deseive S, Stolz L, Stocker TJ, Stark K, et al. Transcatheter edge‐to‐edge repair for tricuspid regurgitation is associated with right ventricular reverse remodeling in patients with right‐sided heart failure. JACC Cardiovasc Imaging 2019;12:559–560. https://doi.org/10.1016/j.jcmg.2018.10.029
Stolz L, Weckbach LT, Hahn RT, Chatfield AG, Fam NP, von Bardeleben RS, et al. 2‐year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol 2023;81:2374–2376. https://doi.org/10.1016/j.jacc.2023.04.014
Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral tricuspid valve replacement and one‐year outcomes: The TRISCEND study. Eur Heart J 2023;44:4862–4873. https://doi.org/10.1093/eurheartj/ehad667